OMS Energy Technologies (NASDAQ: OMSE) is a growth-oriented manufacturer of surface wellhead systems and oil country tubular goods for the oil and gas industry. The company recently closed its initial public offering of 3,703,704 ordinary shares, each at a public offering price of US$9.00, for a total base size of US$33.3 million. The ordinary shares began trading on the Nasdaq Capital Market under the symbol…
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that Founder and CEO Dr. Jonathan Javitt will deliver a company update at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida. NRx is one of six companies invited to present at the high-profile event, which is expected to draw more than 1,000 attendees representing over $1 trillion in investment capital. The presentation…
Beeline Holdings (NASDAQ: BLNE) announced the appointment of Frank Knuettel II to its board of directors, effective immediately. Knuettel brings over 20 years of executive leadership experience across early-stage public companies in technology and life sciences, and currently serves as CEO of Channel Therapeutics Corporation. Known for his capital markets expertise and M&A success, including leading Unrivaled Brands from $10 million to $100 million in…
VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH), announced the appointment of Rick Austin, Ph.D., as Chief Scientific Officer, effective May 1. Dr. Austin brings more than 25 years of oncology research and development leadership and will help drive VERAXA’s BiTAC(TM) platform and clinical-stage pipeline. He previously served as VP of Research at Harpoon Therapeutics (acquired…
NextPlat (NASDAQ: NXPL, NXPLW) announced that its subsidiary, Global Telesat Communications Ltd (GTC), has been appointed the exclusive distributor for ZOLEO Inc. across the UK and European Economic Area. ZOLEO's flagship global satellite communicator extends smartphone messaging coverage via the Iridium(R) satellite network and has earned accolades including Outdoor Retailer’s Innovation Award "Product of the Year." The partnership adds to GTC’s expanding e-commerce and Amazon…
Mullen Automotive (NASDAQ: MULN) reported $5 million in revenue for the quarter ended March 31, 2025, a significant increase from $33,000 in the prior-year period, driven by deliveries of Class 1 and Class 3 electric vehicles to customers including logistics firms, local governments and universities. The company also highlighted new agreements, such as a supply deal with Enpower Greentech for advanced solid-state batteries and expanded…
Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for its lead compound, Lucid-21-302 (Lucid-MS), targeting multiple sclerosis. The IND submission to the FDA is planned for the fourth quarter of 2025 and, if accepted, would enable the company to initiate a Phase 2 clinical trial. Lucid-21-302 is a patented, non-immunomodulatory neuroprotective…
Cybin (NYSE American: CYBN) (NEO: CYBN) welcomed recent comments from FDA Commissioner Dr. Martin Makary endorsing the accelerated development of psychedelic therapeutics. The company, which is conducting Phase 3 trials of CYB003 for major depressive disorder (MDD) and Phase 2 trials of CYB004 for generalized anxiety disorder (GAD), said the FDA’s openness validates its mission to develop next-generation neuropsychiatric treatments. CYB003, a deuterated psilocin candidate,…
Datavault AI (NASDAQ: DVLT), a leader in AI-powered data experience, valuation and monetization, announced it expects to finalize the acquisition of CompuSystems Inc. (CSI) assets today, May 20, 2025. In conjunction with the milestone, the company will host a business update call at 9 a.m. ET. CEO Nathaniel Bradley said the acquisition marks a pivotal step in Datavault’s growth strategy, positioning it to automate and…
Thumzup (NASDAQ: TZUP) announced that CEO Robert Steele will present at the 82nd Emerging Growth Conference on May 21, 2025, at 11:25 a.m. ET. The company will showcase its disruptive platform that pays everyday consumers to post about participating brands on social media, enabling scalable, user-generated advertising. Hosted virtually, the conference highlights innovative small- and micro-cap companies positioned for long-term growth. To view the full…
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health innovations, announced its decision to terminate the Arrangement Agreement with Appili Therapeutics Inc., effective May 31, 2025. The agreement, first announced in April 2024, had been amended multiple times to address evolving conditions. Aditxt cited a lack of strategic alignment as the reason for discontinuing the deal, despite ongoing respect for Appili’s work. Management plans to…
Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing, successfully completed a full workforce drug screening for Barcaldine Regional Council in Queensland, Australia, using its Intelligent Fingerprinting Drug Screening System. Over 160 employees were tested and cleared within 90 minutes, significantly reducing operational disruption compared to traditional methods. The on-site, fingerprint-based solution enabled same-day results and supported immediate workforce return, highlighting…
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (CSE: SUNN) posted fiscal Q3 results for the period ended March 31, 2025, showing year-to-date revenue of C$29.1 million versus C$50.4 million a year earlier, reflecting a shift toward long-term asset ownership over short-term EPC sales. The company reported a net loss of C$9 million compared to net income of C$5.5 million last year, driven by…
Silo Pharma (NASDAQ: SILO) a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed a public offering totaling approximately $2 million in gross proceeds. The offering included 3,333,338 shares of common stock or pre-funded warrants, along with Series A-1 and Series A-2 warrants, each allowing the purchase of up to 3,333,338 shares at $0.60 per share. The Series A-1 Warrants expire…
Capstone Holding (NASDAQ: CAPS) reaffirmed its 2025 targets of a $100 million revenue run-rate and $10 million in adjusted EBITDA, supported by a strong M&A pipeline and disciplined cost control. The company is evaluating acquisition opportunities at 4–6x EBITDA multiples, with up to 45% non-cash consideration, and has secured an equity line of credit to support deals without upfront dilution. Subsidiary Instone remained on track…
Bionoid Pharma (OTC PINK: BINP) has rebranded as AI Maverick Intel, Inc., signaling a strategic pivot toward artificial intelligence-powered customer acquisition and engagement solutions. The transformation follows the acquisition of AI Maverick Intel, a platform specializing in AI-based audience automation and intelligent two-way communication. The company aims to deploy its proprietary technology across healthcare, biotech, and other sectors to enhance targeting, engagement, and operational efficiency. …
FingerMotion (NASDAQ: FNGR), has entered the Indonesian market via its subsidiary, Finger Motion Financial Company Limited, by signing an agreement with PT Mach Wireless Teknologi to deploy its AI-driven insurance risk rating platform. Tailored for local underwriting in motor, health, and life insurance, the platform will integrate with Indonesia’s telco-insurance ecosystem. The company is in final talks with a major Indonesian telecom provider to support…
CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287…
NanoViricides, Inc. (NYSE American: NNVC) filed its Q1 2025 report and announced progress on NV-387, its broad-spectrum antiviral drug candidate. The company has received clearance from the DRC's National Ethics Committee to submit a Phase II trial application for MPox and is also initiating programs targeting measles and avian flu. NV-387 previously completed Phase I with no adverse events and has shown superior activity in…
Silo Pharma (NASDAQ: SILO) has priced a public offering of approximately 3.33 million shares of common stock (or pre-funded warrants) along with Series A-1 and Series A-2 warrants, all priced at $0.60 per unit. The Series A-1 and A-2 warrants are immediately exercisable at $0.60 per share, with expirations set at five years and eighteen months, respectively. Gross proceeds are expected to total roughly $2…
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (CSE: SUNN) President and CEO Dr. Richard Lu appeared on the GotStocks Podcast to discuss the company’s vertically integrated model and its $184 million portfolio of revenue-generating clean energy assets. Lu detailed how SolarBank develops, builds, owns, and operates distributed and community solar projects across Canada and the U.S., including partnerships with Honeywell and Qcells. He…
NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing to $3.8 million. The company advanced regulatory and commercial milestones for its two lead programs: NRX-100, a preservative-free IV ketamine formulation for suicidal depression now supported by an NDA fee waiver and new patent filing; and NRX-101, an…
Adageis, a forward-thinking healthcare technology company, is empowering clinics and medical groups to succeed in the shift from fee-for-service to value-based care through its AI-powered platform. The company’s ProActive Care solution deciphers complex insurance contracts, integrates with leading EHR systems, and offers real-time analytics to help providers track revenue trends as well as their performance and profitability. Proprietary components of the platform, including the Value-Based…
Nutriband (NASDAQ: NTRB), a company focused on the development of a portfolio of transdermal pharmaceutical products, is expanding its market presence and manufacturing capabilities through two new strategic partnerships. The company is collaborating with Charlotte FC to build brand visibility, particularly for its AI Tape and AVERSA(TM)—Nutriband’s proprietary technology that it believes has the potential to be the world’s first and only abuse deterrent patch…
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted this week in a Zacks Small-Cap Research report that presented a favorable analysis, noting that the company’s Phase 3 cutaneous T-cell lymphoma (“CTCL”) study is continuing and that the trial has a high probability of success. According to the report, Soligenix is conducting a Phase 3 FLASH2 trial of HyBryte(TM) in patients with…
NRx Pharmaceuticals (NASDAQ: NRXP) announced that its wholly owned subsidiary, HOPE Therapeutics(TM), has signed a term sheet with Universal Capital, LLC for $7.8 million in acquisition funding to support the rollout of its national interventional psychiatry clinic network. Combined with previously announced investments, HOPE now has $10.3 million in capital to execute initial acquisitions of Dura Medical, Kadima, and NeuroSpa. These clinics offer neuroplastic treatments…
Intelligent Bio Solutions (NASDAQ: INBS) reported continued commercial growth, surpassing 450 active accounts with 35 added in fiscal Q3, driven by demand for its rapid, non-invasive fingerprint drug testing system. The company expanded into new sectors including luxury marine, retail, and waste management, while entering remote regions across Europe and Australia. INBS now operates in 24 countries and partners with 18 distributors across 19 nations.…
Telomir Pharmaceuticals (NASDAQ: TELO) announced the identification of Telomir-Ag2, a stabilized Silver(II) complex demonstrating potent, broad-spectrum antimicrobial activity, including against drug-resistant MARSA. Developed using the company’s proprietary Telomir-1 platform, Telomir-Ag2 is the first Silver(II) compound to achieve biological compatibility, outperforming its Silver(I) predecessor in preclinical studies. Designed for use in high-risk infections such as burns and surgical wounds, the drug candidate targets the growing $1.36…
Datavault AI (NASDAQ: DVLT) filed Q1 2025 results and reaffirmed its 2026 revenue target of $40 million to $50 million, projecting $12 million to $15 million in revenue in the second half of 2025. The company expects to close its acquisition of CompuSystems Inc. during the week of May 19. Recent strategic milestones include joining IBM’s Partner Plus, licensing its ADIO(R) ultrasonic advertising tech to…
Calidi Biotherapeutics (NYSE American: CLDI) reported a Q1 2025 net loss of $5.0 million, narrowing from $7.2 million in the prior year, with R&D and G&A expenses also declining. The company highlighted FDA clearance of its IND for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, and presented promising Redtail platform data at AACR showcasing IL15 superagonist delivery via engineered oncolytic virus. Calidi also…
Brera Holdings (NASDAQ: BREA) welcomed reports that Eagle Football Holdings, a $2 billion multi-club ownership group, is preparing to file for an IPO. Eagle’s portfolio includes stakes in Crystal Palace, Lyon, Botafogo, and Molenbeek. Brera Executive Chairman Dan McClory expressed support for the move, citing its potential to raise investor awareness of the MCO model and sports as an asset class. Brera, which completed its…
Cybin (NYSE American: CYBN) (NEO: CYBN) has partnered with Thermo Fisher Scientific to support Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin treatment for major depressive disorder (MDD). The agreement expands on Cybin’s existing U.S.-based manufacturing operations, with Thermo Fisher handling drug substance in South Carolina and capsule production in Ohio. CYB003 received FDA Breakthrough Therapy Designation in March…
SKYX Platforms (NASDAQ: SKYX) reported record Q1 2025 revenue of $20.1 million, up 6% year-over-year, driven by growth in its smart and standard plug & play product sales. The company’s gross profit rose to $5.7 million while net loss per share narrowed to ($0.09). SKYX raised $4 million in new equity as part of a $15 million financing round led by The Shaner Group and…
Silo Pharma (NASDAQ: SILO) has partnered with Veloxity Labs to conduct GLP-compliant bioanalysis for its ongoing toxicology and toxicokinetics study of SPC-15, an intranasal treatment aimed at preventing PTSD. The data will support an FDA investigational new drug submission expected in 2025. If approved, Silo plans to advance SPC-15 into a Phase 1 human clinical trial. To view the full press release, visit https://ibn.fm/Bo8ag About…
Newton Golf Company (NASDAQ: NWTG) reported a 246% year-over-year revenue increase to $1.2 million in Q1 2025, driven by surging demand for its Newton Motion and Fast Motion shafts. Gross profit rose to $852,000 with margin expansion to 70%, while net loss narrowed to $0.5 million. More than 30 professionals have adopted Newton shafts, including 8 new players across major tours in Q1. The company…
G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) reported Q1 2025 gold production of 35,578 ounces at an all-in sustaining cost of $960/oz, generating $24.4 million in net income and $36.0 million in free cash flow. With $149 million in cash and no lost time or recordable incidents, the company remains on track to meet 2025 guidance. GMIN advanced early works at Oko West and…
Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) has initiated a series of investor awareness and marketing agreements aimed at expanding its visibility. The Company engaged InvestorBrandNetwork for a yearlong communications campaign starting May 8, 2025, at $23,200 per quarter, and Goldinvest Consulting for six months beginning May 5 to support outreach in Germany at EUR 4,050 per month. Ucore also signed a 12-month media agreement…
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) will release its financial results for the quarter ended March 31, 2025, after market close today, May 15, and will host a webinar at 4:30 p.m. ET to provide a business update and discuss the quarterly performance. To view the full press release, visit https://ibn.fm/PSk5q About SolarBank Corporation SolarBank Corporation is…
NextPlat (NASDAQ: NXPL, NXPLW) reported Q1 2025 revenue of $14.5 million, down from $17.5 million in the prior year, driven by changes in 340B pharmacy agreements and prescription volume. Gross margin declined to 23.8%, while operating expenses fell 26% to $4.9 million due to reduced legal and non-recurring costs. Net loss narrowed to $1.3 million, or ($0.05) per share. The company ended the quarter with…
NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15. A conference call and webcast will follow at 4:30 p.m. ET, accessible via the company’s investor relations site or by dialing +1-800-717-1738 (U.S.) or +1-646-307-1865 (international). The earnings update comes shortly after news that NRx’s wholly owned subsidiary, HOPE Therapeutics, signed a…
To distribute a release in the next 24 hours. Contact our client services team.
Distribute a press release. Submit your release to get started.
Set up a Live demonstration. Schedule a date and time that works for you.
All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.
Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).